Histone deacetylase inhibition by valproic acid down-regulates c-FLIP/CASH and sensitizes hepatoma cells towards CD95- and TRAIL receptor-mediated apoptosis and chemotherapy

Oncology Reports

Volumn 15, Issue 1, 2006, Pages 227-230

  Schuchmann, Marcus ^a   Schulze Bergkamen, H ^a   Fleischer, B ^a   Schattenberg, J M ^a   Siebler, J ^a   Weinmann, A ^a   Teufel, A ^a   Worns M ^a   Fischer, T ^a   Strand, S ^a   Lohse, A W ^b   Galle, P R ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Apoptosis; CD95; Epirubicin; Hepatocellular carcinoma; Histone deacetylase inhibitors; TNF related apoptosis inducing ligand

Indexed keywords

ANTINEOPLASTIC AGENT; APOPTOSIS REGULATORY PROTEIN; CASP3 PROTEIN, HUMAN; CASPASE; CASPASE 3; CFLAR PROTEIN, HUMAN; EPIRUBICIN; FAS ANTIGEN; FLICE INHIBITORY PROTEIN; HISTONE DEACETYLASE; MEMBRANE PROTEIN; SIGNAL PEPTIDE; TNFSF10 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VALPROIC ACID;

APOPTOSIS; ARTICLE; DOWN REGULATION; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; DRUG RESISTANCE; ENZYMOLOGY; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM;

ANTIGENS, CD95; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CARCINOMA, HEPATOCELLULAR; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CASPASE 3; CASPASES; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; EPIRUBICIN; HISTONE DEACETYLASES; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER NEOPLASMS; MEMBRANE GLYCOPROTEINS; RECEPTORS, TUMOR NECROSIS FACTOR; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA; VALPROIC ACID;

EID: 33644876853     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.15.1.227     Document Type: Article

References (33)

1. Llovet JM, Burroughs A and Bruix J: Hepatocellular carcinoma. Lancet 362: 1907-1917, 2003. (Pubitemid 37518510)
2. Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V, Bodmer JL, Schroter M, Burns K, Mattmann C, Rimoldi D, French LE and Tschopp J: Inhibition of death receptor signals by cellular FLIP. Nature 388: 190-195, 1997. (Pubitemid 27297457)
3. Goltsev YV, Kovalenko AV, Arnold E, Varfolomeev EE, Brodianskii VM and Wallach D: CASH, a novel caspase homologue with death effector domains. J Biol Chem 272: 19641-19644, 1997. (Pubitemid 27340049)
4. Okano H, Shiraki K, Inoue H, Kawakita T, Yamanaka T, Deguchi M, Sugimoto K, Sakai T, Ohmori S, Fujikawa K, Murata K and Nakano T: Cellular FLICE/caspase-8-inhibitory protein as a principal regulator of cell death and survival in human hepatocellular carcinoma. Lab Invest 83: 1033-1043, 2003. (Pubitemid 36899070)
5. Shu HB, Halpin DR and Goeddel DV: Casper is a FADD- and caspase-related inducer of apoptosis. Immunity 6: 751-763, 1997. (Pubitemid 27305737)
6. Hu S, Vincenz C, Ni J, Gentz R and Dixit VM: I-FLICE, a novel inhibitor of tumor necrosis factor receptor-1- and CD-95-induced apoptosis. J Biol Chem 272: 17255-17257, 1997. (Pubitemid 27311147)
7. Srinivasula SM, Ahmad M, Ottilie S, Bullrich F, Banks S, Wang Y, Fernandes-Alnemri T, Croce CM, Litwack G, Tomaselli KJ, Armstrong RC and Alnemri ES: FLAME-1, a novel FADD-like anti-apoptotic molecule that regulates Fas/TNFR1-induced apoptosis. J Biol Chem 272: 18542-18545, 1997. (Pubitemid 27318191)
8. Inohara N, Koseki T, Hu Y, Chen S and Nunez G: CLARP, a death effector domain-containing protein interacts with caspase-8 and regulates apoptosis. Proc Natl Acad Sci USA 94: 10717-10722, 1997. (Pubitemid 27430800)
9. Han DK, Chaudhary PM, Wright ME, Friedman C, Trask BJ, Riedel RT, Baskin DG, Schwartz SM and Hood L: MRIT, a novel death-effector domain-containing protein, interacts with caspases and BclXL and initiates cell death. Proc Natl Acad Sci USA 94: 11333-11338, 1997.
10. Rasper DM, Vaillancourt JP, Hadano S, Houtzager VM, Seiden I, Keen SL, Tawa P, Xanthoudakis S, Nasir J, Martindale D, Koop BF, Peterson EP, Thornberry NA, Huang J, Black SC, MacPherson DP, Hornung F, Lenardo MJ, Hayden MR, Roy S and Nicholson DW: Cell death attenuation by 'usurpin', a mammalian DED-caspase homologue that precludes caspase-8 recruitment and activation by the CD-95 (Fas, APO-1) receptor complex. Cell Death Differ 5: 271-288, 1998. (Pubitemid 28356540)
11. Morinaga S, Nakamura Y, Ishiwa N, Yoshikawa T, Noguchi Y, Yamamoto Y, Rino Y, Imada T, Takanashi Y, Akaike M, Sugimasa Y and Takemiya S: Expression of survivin mRNA associates with apoptosis, proliferation and histologically aggressive features in hepatocellular carcinoma. Oncol Rep 12: 1189-1194, 2004.
12. Shin EC, Shin JS, Park JH, Kim JJ, Kim H and Kim SJ: Expression of Fas-related genes in human hepatocellular carcinomas. Cancer Lett 134: 155-162, 1998. (Pubitemid 29070732)
13. Llovet JM and Bruix J: Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 37: 429-442, 2003. (Pubitemid 36152543)
14. Johnstone RW: Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 1: 287-299, 2002.
15. Ogawa K, Yasumura S, Atarashi Y, Minemura M, Miyazaki T, Iwamoto M, Higuchi K and Watanabe A: Sodium butyrate enhances Fas-mediated apoptosis of human hepatoma cells. J Hepatol 40: 278-284, 2004. (Pubitemid 38115833)
16. Herold C, Ganslmayer M, Ocker M, Hermann M, Geerts A, Hahn EG and Schuppan D: The histone-deacetylase inhibitor Trichostatin A blocks proliferation and triggers apoptotic programs in hepatoma cells. J Hepatol 36: 233-240, 2002. (Pubitemid 34146430)
17. Gottlicher M, Minucci S, Zhu P, Kramer OH, Schimpf A, Giavara S, Sleeman JP, Lo Coco F, Nervi C, Pelicci PG, Heinzel T, Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA and Klein PS: Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells histone deacetylase is a direct target of valproic acid, a potent anti-convulsant, mood stabilizer, and teratogen. EMBO J 20: 6969-6978, 2001.
18. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA and Klein PS: Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 276: 36734-36741, 2001.
19. Insinga A, Monestiroli S, Ronzoni S, Gelmetti V, Marchesi F, Viale A, Altucci L, Nervi C, Minucci S and Pelicci PG: Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med 11: 71-76, 2005. (Pubitemid 40215840)
20. Nebbioso A, Clarke N, Voltz E, Germain E, Ambrosino C, Bontempo P, Alvarez R, Schiavone EM, Ferrara F, Bresciani F, Weisz A, de Lera AR, Gronemeyer H and Altucci L: Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat Med 11: 77-84, 2005. (Pubitemid 40215841)
21. Trauth BC, Klas C, Peters AM, Matzku S, Moller P, Falk W, Debatin KM and Krammer PH: Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 245: 301-305, 1989. (Pubitemid 19196649)
22. Scaffidi C, Schmitz I, Krammer PH and Peter ME: The role of c-FLIP in modulation of CD95-induced apoptosis. J Biol Chem 274: 1541-1548, 1999.
23. Schuchmann M, Hess S, Bufler P, Brakebusch C, Wallach D, Porter A, Riethmuller G and Engelmann H: Functional discrepancies between tumor necrosis factor and lymphotoxin alpha explained by trimer stability and distinct receptor interactions. Eur J Immunol 25: 2183-2189, 1995.
24. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F and Riccardi C: A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 139: 271-279, 1991.
25. Schuchmann M and Galle PR: Sensitizing to apoptosis - sharpening the medical sword. J Hepatol 40: 335-336, 2004. (Pubitemid 38115842)
26. Singh TR, Shankar S and Srivastava RK: HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma. Oncogene 24: 4609-4623, 2005. (Pubitemid 41032599)
27. Bin L, Li X, Xu LG and Shu HB: The short splice form of Casper/c-FLIP is a major cellular inhibitor of TRAIL-induced apoptosis. FEBS Lett 510: 37-40, 2002. (Pubitemid 34084880)
28. Armeanu S, Pathil A, Venturelli S, Mascagni P, Weiss TS, Gottlicher M, Gregor M, Lauer UM and Bitzer M: Apoptosis on hepatoma cells, but not on primary hepatocytes by histone deacetylase inhibitors valproate and ITF2357. J Hepatol 42: 210-217, 2005. (Pubitemid 40143467)
29. Jo M, Kim TH, Seol DW, Esplen JE, Dorko K, Billiar TR and Strom SC: Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med 6: 564-567, 2000. (Pubitemid 30305907)
30. Ichikawa K, Liu W, Zhao L, Wang Z, Liu D, Ohtsuka T, Zhang H, Mountz JD, Koopman WJ, Kimberly RP and Zhou T: Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med 7: 954-960, 2001. (Pubitemid 32756434)
31. Gores GJ and Kaufmann SH: Is TRAIL hepatotoxic? Hepatology 34: 3-6, 2001. (Pubitemid 32591476)
32. Hao C, Song JH, Hsi B, Lewis J, Song DK, Petruk KC, Tyrrell DL and Kneteman NM: TRAIL inhibits tumor growth, but is nontoxic to human hepatocytes in chimeric mice. Cancer Res 64: 8502-8506, 2004. (Pubitemid 39552059)
33. Yagita H, Takeda K, Hayakawa Y, Smyth MJ and Okumura K: TRAIL and its receptors as targets for cancer therapy. Cancer Sci 95: 777-783, 2004. (Pubitemid 39545582)